Low-Dose Sirolimus Immunoregulation Therapy in Patients with Active Rheumatoid Arthritis: A 24-Week Follow-Up of the Randomized, Open-Label, Parallel-Controlled Trial

Figure 2

Efficacy of sirolimus in reducing disease activity. Mean DAS28-ESR score (a), ESR (b), mean number of tender joints (c), and swollen joints (d). Overall changes during treatment were assessed by repeated measure analysis using a mixed-effect model. A two-tailed unpaired -test was used to compare the disease activity measures between sirolimus and conventional groups. Error bars show SD. DAS28: 28-joint disease activity score; ESR: erythrocyte sedimentation rate. ^#, ^##, and ^### relative to baseline (week 0) in the conventional group (blue); ^#, ^##, and ^### relative to baseline in the sirolimus group (red); compared between groups.

(a)

(b)

(c)

(d)